Image-guided biopsy uses imaging technologies to examine the inside of the body. The biopsy allows the medical expert to readily obtain a sample of the suspicious cell by inserting the needle into the optimum position. It is regarded as one of the greatest methods of collecting samples because it produces no significant harm. As pictures are required to guide the placement of the needle during a biopsy, this technique is often performed in one of the two locations, such as in the Interventional Radiology (IR) suite using ultrasound (sound waves) or fluoroscopy (X-rays), or in the CT room with a CT scanner.
COVID-19 Impact Analysis
Globally, the COVID-19 pandemic has impacted routine hospital services. Elective procedures are being reduced significantly in order to reduce the risk of infection and to transform operating rooms into COVID-19 emergency facilities. The vast majority of participants cancelled planned appointments, routine check-ups, or chronic condition treatment. To resume elective procedures, various safety standards must be followed, such as maintaining sanitation, isolating patients before and after surgery, and testing patients for COVID-19 before they are admitted for the surgery. Delaying routine or preventative screenings was acceptable during the pandemic's beginning stage, especially with patients using efficient telemedicine services. As a result, COVID-19 is expected to have a substantial impact on the image-guided biopsy market.
Top Impacting Factors
- One of the primary factors to drive the growth of the image-guided biopsy market is the rise in the occurrences of chronic diseases such as cancer among the global population.
- Initiatives done by the government and health organizations globally to raise disease awareness and promote R&D activities to improve treatment facilities accelerate the expansion of the image-guided biopsy market.
- The rise in the preference for less invasive procedures due to factors such as the low risk of injury and increased awareness of the benefits of early diagnosis has a positive impact on the image-guided biopsy market.
- Furthermore, the aging population, the increase in public awareness of diseases and treatment choices, improved healthcare infrastructure, the increase in investment, and he rise in healthcare expenditure, all have a beneficial impact on the image-guided biopsy market.
- Furthermore, technological advances and innovations are expected to provide profitable chances to image-guided biopsy market players during the forecast period.
- On the other hand, the rise in concerns about the danger of infection involved with the use of aspiration and biopsy needles is projected to hamper the expansion of the image-guided biopsy market.
Market Trends
New Product Launches to Flourish Image-guided Biopsy Market
In January 2019, IZI Medical Products acquired Cook Medical’s soft tissue biopsy and breast localization needle product line.
In February 2018, Merit Medical Systems, Inc. announced the closure of its purchase of divestment assets from BD (Becton, Dickinson, and Company).
In September 2018, EZ Shot 3 Plus 25 G EUS single-use needle, developed by Olympus Corporation for fine-needle biopsy and aspiration, received a FDA approval. The needle can be used to study submucosal and extramural lesions found in various sections of the gastrointestinal tract. Merit Medical Systems Inc. launched five new manual bone biopsy systems for upper-spine, deep-bone, and narrow-access procedures in the same month.
The rise in incidences of cancer is the most important factor to drive the growth of the image-guided biopsy market. According to the World Health Organization (WHO), 21.4 million more patients will be diagnosed with malignant tumors in 2030, up from 12.7 million in 2008. Furthermore, cancer took the lives of 9.6 million people globally in 2018. Biopsy and aspiration are commonly used to explore the nature of tumors by removing a portion of the tissue or fluid in concern and analyze it. With the rising cancer burden, healthcare professionals and government agencies are stepping up efforts to deliver improved diagnostic services, leading to an increase in demand for the image-guided biopsy market.
Key Benefits of Report
- This study presents the analytical depiction of the image-guided biopsy market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the image-guided biopsy market share.
- The current market is quantitatively analyzed to highlight the image-guided biopsy market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the image-guided biopsy market.
- The report provides a detailed image-guided biopsy market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions Answered in Image-Guided Biopsy Market Report
- Who are the leading market players active in the image-guided biopsy market?
- What current trends will influence the image-guided biopsy market in the next few years?
- What are the driving factors, restraints, and opportunities in the image-guided biopsy market?
- What future projections would help in taking further strategic steps?
- What is image-guided biopsy?
- What is the image-guided biopsy market prediction for the future?
- Who are the leading global players in the image-guided biopsy market?
- What are the current trends and predicted trends?
- What are the key benefits of the image-guided biopsy market report?
Image-Guided Biopsy Market Report Highlights
| Aspects | Details |
 By Technology |
|
 By Process |
|
 By End User |
|
 By Region |
|
 Key Market Players | Hologic Inc., Varian Medical Systems, Inc., Olympus Corporation, Brainlab, Siemens Healthcare GmbH, Stryker, GENERAL ELECTRIC, Analogic Corporation, KARL STORZ Endoscopy India Pvt. Ltd., Medtronic,, Koninklijke Philips N.V. |
Loading Table Of Content...
